ClinicalTrials.gg
TerminatedNCT05601752Updated Oct 19, 2026

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

A Phase 2 interventional study of Autologous genetically modified ADP-A2M4CD8 cells and Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab in Ovarian Cancer, sponsored by USWM CT, LLC. Terminated at 23 sites in 5 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by USWM CT, LLC · Phase 2, Interventional, and Treatment

Why this study was terminated
Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2026.
Updated Oct 19, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Enrollment
1,114th of 1,498
21 · median 47
Started
2023
with 66 others
Phase 2
485 of 1,779
53 open now
Registered
1,494th of 1,779
by date

Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 1,114th largest by enrollment of the 1,498 interventional ones that give a count, is one of 67 that started in 2023, is one of 485 in phase 2, and was the 1,494th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

273 more — sign in →

All 278 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,779 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subjects will be assessed for eligibility prior to leukapheresis AND prior to lymphodepleting chemotherapy (unless otherwise noted) and must meet all specified criteria for study participation.

Inclusion Criteria:

  1. Subject (or legally authorized representative) has voluntarily agreed to participate by giving written in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines and applicable local regulations.
  2. Subject (or legally authorized representative) has agreed to abide by all protocol-required procedures including study related assessments and management by the treating institution for the duration of the study, including LTFU.
  3. Subject is ≥ 18 and ≤ 75 years of age at the time the Pre Screening informed consent form (ICF) is signed.
  4. Subject has confirmed diagnosis of high-grade serous or high-grade endometrioid recurrent ovarian carcinoma, including primary peritoneal and fallopian tube carcinoma.
  5. Subject has according to v1.1 prior to lymphodepletion. Measurable disease is not required prior to leukapheresis.
  6. Subject has the following disease-specific prior therapy requirements:

    1. The initial therapy must have included at least 3 cycles of a prior platinum and taxane based chemotherapy regimen for primary disease, possibly including intraperitoneal therapy, consolidation, or extended therapy (maintenance/consolidation).
    2. Subjects may receive up to 4 prior regimens of combination or single agent systemic treatment for their disease, which may include therapies unless discussed and agreed upon with the Sponsor or designee. Note: /adjuvant treatment is considered as one . Bridging therapy is permitted and is not considered as a line of treatment.
    3. Subjects who have received only 1 line of platinum based therapy must have progressed between 93 and 183 days of completing platinum based therapy as a part of front line treatment of ovarian cancer. Subjects who have progressed within 92 days of completing platinum based therapy in front line treatment are excluded.
    4. Subjects who have received 2 or more lines of platinum based therapy must have progressed during or within 183 days of completing the latest platinum based therapy for treatment of recurrent ovarian cancer. The number of days (platinum-free interval) should be calculated from the date of the last administered dose of platinum therapy to the date of documentation of progression.
    5. Subjects with a known BRCA mutation (germ line or somatic) must have received a poly adenosine diphosphate-ribose polymerase (PARP).
    6. Subjects must have received bevacizumab.
  7. Positive for HLA-A*02:01, HLA-A*02:02, HLA-A*02:03, or HLA-A*02:06 allele as determined by Adaptimmune-designated central laboratory testing. HLA-A*02 alleles having the same protein sequence in the peptide binding domains (P group) will also be included. Other HLA-A*02 alleles may be eligible after adjudication with the Sponsor.
  8. MAGE-A4 expression, defined as ≥ 30% of tumor cells that are ≥ 2+ by IHC, should be documented at the pre screening period based on either an or a fresh biopsy. All samples must have been pathologically reviewed by an Adaptimmune-designated central laboratory confirming expression.
  9. Subject has an (ECOG) performance status (PS) of 0 or 1.
  10. Subject has (LVEF) of ≥ 50% or the institutional lower limit of normal range, whichever is lower.
  11. Subject is fit for leukapheresis, and adequate venous access can be established for the cell collection.
  12. Subjects of must have a negative urine or serum pregnancy test AND must agree to use a highly effective method of starting at the first dose of chemotherapy and continue for at least 12 months or for 4 months after the gene-modified cells are no longer detected in the blood, or 6 months after the last dose of nivolumab, whichever is longer. Subjects of childbearing potential must also agree to refrain from egg donation, storage, or banking during these same time periods.
  13. Subjects must have ≥ 90% room air oxygen saturation test at rest at Screening (within 7 days of leukapheresis) and at Baseline.
  14. Subject must have adequate organ function as indicated by the laboratory values in the table below.

System Laboratory Value Hematological (ANC) ≥ 1.5 × 109/L (without granulocyte colony stimulating factor [G-CSF] support) ≥ 100 × 109/L (without transfusion support within 5 days prior to leukapheresis and lymphodepletion) (Hb) ≥ 90 g/L (without transfusion support within 5 days prior to leukapheresis and lymphodepletion) Coagulation or international normalized ratio (INR) ≤ 1.5 × (ULN), unless receiving therapeutic anticoagulation Partial thromboplastin time ≤ 1.5 × ULN, unless receiving therapeutic anticoagulation Renal (GFR) or (CrCl) (estimated or calculated)1 ≥ 50 mL/min /1.73 m2 or ≥ 50 mL/min Hepatic Serum total ≤ 1.5 × ULN (unless subject has documented Gilbert's Syndrome with direct bilirubin \< 35% of total bilirubin) Exception: Subjects with liver ≤ 2.5 × ULN (ALT) / Aspartate aminotransferase (AST) ≤ 2.5 × ULN Albumin ≥ 3 g/dL (Without albumin deficit replacement within 7 days only prior to leukapheresis) Exception: Subjects with liver metastasis ≤ 5.0 × ULN

1 Renal function (GFR or CrCl) will be estimated or measured according to standard practice at the treating institution. Renal function will be reassessed at Baseline using the same methodology.

Note: Laboratory values that are slightly out of the laboratory test parameters, if assessed as not by the site study Investigator, may be acceptable after discussion and review by the Sponsor Study Physician. This applies to screening laboratory assessments and baseline laboratory assessments.

Exclusion Criteria:

  1. Positive for HLA-A*02:05 in either allele as determined by Adaptimmune-designated central laboratory testing. HLA-A*02 alleles having the same protein sequence as HLA-A*02:05 in the peptide binding domains (P groups) will also be excluded. Other alleles may be exclusionary after adjudication with the Sponsor.
  2. Subject has received or plans to receive the following therapy/treatment prior to to leukapheresis or lymphodepleting chemotherapy, unless stopped according to the requirements:

    Cytotoxic chemotherapy Required Washout Prior to Leukapheresis 3 weeks Required Washout Prior to Lymphodepletion: 3 weeks

    Small molecules/tyrosine kinase inhibitors (TKIs), such as dabrafenib, trametinib, vemurafenib, and cobimetinib Note: No washout period is required for compounds that do not cause bone marrow suppression/lymphopenia or for epidermal growth factor receptor and alkaline phosphatase/ ROS 1 inhibitors. Required Washout Prior to Leukapheresis 1 week Required Washout Prior to Lymphodepletion: 1 week

    Immune therapy (including monoclonal antibody therapy, , and biologics) other than anti-PD(L)1 Required Washout Prior to Leukapheresis 2 weeks Required Washout Prior to Lymphodepletion: 2 weeks

    Anti-PD(L)1 Required Washout Prior to Leukapheresis 2 weeks Required Washout Prior to Lymphodepletion: 6 weeks

    Experimental anti-cancer vaccine Required Washout Prior to Leukapheresis: N/A Required Washout Prior to Lymphodepletion: Eight weeks in the absence of tumor response.

    The subject should be excluded if their disease is responding to an experimental vaccine given within 6 months.

    Gene therapy using an integrating vector Subjects who have received a gene therapy using any DNA-integrating vector other than a lentivirus (retrovirus, Adeno-associated Virus (AAV), etc.) are excluded from this study. Use of previous gene therapy using a lentiviral vector is permitted. If transduced T-cells represent \< 1% of PBMCs (\< 1500 copies of vectors/μg of PBMC DNA) at the time of screening. Eligibility testing must be done by Adaptimmune's designated Contract Research Organization (CRO). Required Washout Prior to Lymphodepletion: N/A

    or any other therapy Note: Use of topical or inhaled steroids is not an exclusion. See Section 6.5.1 for exceptions.

    Required Washout Prior to Leukapheresis: 2 weeks Required Washout Prior to Lymphodepletion 2 weeks

    Anti-MAGE-A4 therapy Note: Fresh screening biopsy post-anti-MAGE-A4 therapy must be obtained to confirm MAGE-A4 positivity by IHC. Required Washout Prior to Leukapheresis: 2 weeks Required Washout Prior to Lymphodepletion: 2 weeks

    Investigational treatment Required Washout Prior to Leukapheresis 2 weeks or 5 half-lives, whichever is shorter Required Washout Prior to Lymphodepletion: 2 weeks or 5 half-lives, whichever is shorter.

    Radiation to vital organs (e.g., liver, kidney) Required Washout Prior to Leukapheresis: N/A Required Washout Prior to Lymphodepletion: 4 weeks

    Radiation to the pelvis Required Washout Prior to Leukapheresis: 4 weeks Required Washout Prior to Lymphodepletion: 4 weeks

    Whole brain radiotherapy (WBRT) or brain stereotactic radiosurgery (SRS) Required Washout Prior to Leukapheresis N/A Required Washout Prior to Lymphodepletion: 2 weeks

    Radiotherapy to the target lesions Required Washout Prior to Leukapheresis: N/A Required Washout Prior to Lymphodepletion: 3 months prior to lymphodepleting chemotherapy or a target lesion with progression post radiotherapy (Note: There is no washout period for palliative radiation to non-target organs.)

    PARP inhibitor Required Washout Prior to Leukapheresis: 1 week Required Washout Prior to Lymphodepletion: 1 week

    Antibody drug conjugates (such as mirvetuximab) Required Washout Prior to Leukapheresis: 3 weeks Required Washout Prior to Lymphodepletion: 3 weeks Note: Duration of any other anti-cancer therapies must be discussed and agreed upon with the Sponsor Study Physician

  3. Toxicity from previous anti-cancer therapy that has not recovered to Grade ≤ 1 or baseline prior to enrollment (except for nonclinically significant toxicities, e.g., alopecia and vitiligo). Subjects with Grade 2 toxicities that are deemed stable or irreversible (e.g., peripheral neuropathy) can be enrolled.
  4. Subject has a history of allergic reactions attributed to compounds of similar chemical or biological composition to fludarabine, cyclophosphamide, or other agents used in the study.
  5. Subject has an active or immune-mediated disease that has not yet been resolved. Subjects with immune-mediated AEs secondary to treatment with immunotherapy that resolve to Grade ≤ 1 off steroids are permitted. Subjects with hypothyroidism, type I diabetes, adrenal insufficiency, or pituitary insufficiency that are stable on replacement therapy are eligible. Subjects with disorders such as asthma, vitiligo, psoriasis, or atopic dermatitis that are well controlled without requiring systemic immunosuppression are also eligible. Other stable immune conditions that do not require prednisone > 20 mg/day (or its equivalent for other corticosteroid agents) may be acceptable with the agreement of the Sponsor.
  6. Subject had major surgery within 4 weeks prior to lymphodepletion; subjects should have been fully recovered from any surgical-related toxicities. Surgical-related toxicities that are not clinically significant per Investigator assessment may be acceptable after discussion and agreement with the Study Physician.
  7. , carcinomatous meningitis, or symptomatic central nervous system (CNS) metastases. Subjects with prior history of symptomatic must have received treatment (i.e., SRS, WBRT, or surgery) and be neurologically stable for at least 1 month, not requiring anti-seizure medications, or off steroids for at least 14 days prior to leukapheresis and lymphodepletion. Subjects who have asymptomatic CNS metastases without associated edema, shift, or requirement for steroids or anti-seizure medications are eligible. If such a subject receives SRS or WBRT, a minimum period of 2 weeks needs to lapse between the therapy and lymphodepletion. Prophylactic anti-seizure medication is allowed.
  8. Subject has any other prior that is not considered by the Investigator to be in complete remission. Resectable squamous or basal cell carcinoma of the skin is acceptable. Prior malignancies that have been surgically resected and show no evidence of disease are acceptable.
  9. Clinically significant cardiovascular disease including, but not limited to, any of the following:

    1. (ECG) showing clinically significant abnormality at Screening
    2. Uncontrolled clinically significant arrhythmias
    3. Known family history or congenital history of prolonged syndrome or history of torsade de pointes
    4. Uncontrolled hypertension despite optimal medical therapy
    5. Acute coronary syndrome (angina or myocardial infarction) in the last 6 months
    6. Clinically significant cardiac disease defined by congestive heart failure Class 3 and 4
    7. History of stroke, CNS bleeding, , or reversible ischemic neurologic deficit within last 6 months
  10. Uncontrolled intercurrent illness including, but not limited to, any of the following:

    1. Ongoing or active systemic infection, or localized infection which may become systemic due to leukapheresis procedure, e.g., catheter insertion will be excluded. Subjects with urinary tract infections will be included only following treatment with antibiotics.(For SARS-CoV 2 [COVID-19] infection, see Section 10.4.4.1)
    2. Clinically significant pulmonary disease with any 1 pulmonary function parameter \< 60% predicted (forced expiratory volume first forced breath [], total lung capacity [TLC], or diffusing capacity of lungs for carbon monoxide [DLCO]; note: for patients with anemia, corrected DLCO could be used) assessed prior to leukapheresis and within 2 months of the start of lymphodepleting chemotherapy
    3. Requirement for oxygen support (due to cardiac or pulmonary disease)
    4. Interstitial lung disease (pneumonitis) or history of pneumonectomy or with ≥ 1 exacerbation within 1 year prior to the Screening Visit that required treatment with systemic corticosteroids or resulted in hospitalization
    5. Hospitalization for bowel obstruction in last 2 months
    6. Hematosis or significant organ bleeding in last 2 months
    7. Ascites or pleural effusion which requires repeated (2 within 4 weeks) paracentesis or thoracentesis within last 2 months
    8. Cardiac or pericardial tumor involvement (prior to lymphodepletion)
  11. Active infection with (HIV), virus (HBV), virus (HCV), or human T cell leukemia virus (HTLV) as defined below. Re-screening for infectious disease markers is not required at baseline (prior to lymphodepletion) unless > 6 months has elapsed.

    1. Positive serology for HIV
    2. Active hepatitis B infection as demonstrated by test for hepatitis B surface antigen. Subjects who are hepatitis B surface antigen negative but are hepatitis B core antibody-positive must have undetectable hepatitis B DNA and receive prophylaxis against viral reactivation. Prophylaxis should be initiated prior to lymphodepleting therapy and continued for 6 months.
    3. Active hepatitis C infection as demonstrated by hepatitis C ribonucleic acid (RNA) test. Subjects who are HCV antibody-positive will be screened for HCV RNA by any reverse transcription-polymerase chain reaction (RT PCR) or branched DNA (bDNA) assay. If HCV antibody is positive, eligibility will be determined based on a negative screening RNA value.
    4. Positive serology for HTLV 1 or 2
  12. Subject is pregnant or breastfeeding.
  13. Subjects who have illicit drug or alcohol dependency within the past year.
  14. In the opinion of the Investigator, subject will be unlikely to fully comply with protocol requirements.
  15. Intolerance to nivolumab includes severe allergic reaction to nivolumab or any components (active or inactive) of nivolumab.
Terms in these criteria, in plain language(40)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Autologous genetically modified ADP-A2M4CD8 cells

    Genetic: Autologous genetically modified ADP-A2M4CD8 cells

  • Experimental
    Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab

    Combination Product: Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab

Interventions

  • GeneticAutologous genetically modified ADP-A2M4CD8 cells

    Infusion of autologous genetically modified ADP-A2M4CD8 cells on Day 1

  • Combination productAutologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab

    Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 followed by nivolumab 480 mg IV at Week 4 and then every four weeks

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. To evaluate the anti-tumor activity of genetically modified autologous T-cells (ADP-A2M4CD8) as monotherapy and in combination with nivolumab in HLA-A*02 positive subjects with MAGE-A4 positive recurrent ovarian cancer

    Overall Response (OR) is defined as incidence of (confirmed) complete responses or partial responses as assessed by RECIST v1.1 by IRAC from T-cell infusion until documented disease progression

    Time frame: 3.6 years

Secondary outcomes

  1. To evaluate safety and tolerability of ADP-A2M4CD8 as monotherapy or in combination with nivolumab

    Determination of incidence of adverse events and incidence, severity, and duration of AESIs

    Time frame: 3.6 years

  2. To evaluate safety of ADP-A2M4CD8 as monotherapy or in combination with nivolumab.

    Incidence of patients with Replication-competent Retrovirus, persistence of ADP-A2M4CD8 T-cells and incidence of insertional oncogenesis.

    Time frame: 15 years

  3. Durable Response (DR)

    DR per RECIST v1.1 by IRAC and Investigator radiological assessment, defined as a confirmed OR (CR or PR) lasting continuously for 6 months and starting any time within 12 months of T-cell infusion

    Time frame: 3.6 years

  4. Time to response (TTR)

    TTR per RECIST v1.1 by IRAC and Investigator radiological assessment, defined as the duration between the date of T-cell infusion and the initial date of the confirmed response.

    Time frame: 3.6 years

  5. Duration of Response (DOR)

    DoR per RECIST v1.1 by IRAC and Investigator radiological assessment, defined as the duration from the initial date of the confirmed response to the earliest date of PD or death due to any cause.

    Time frame: 3.6 years

  6. Progression Free Survival (PFS)

    PFS per RECIST v1.1 by IRAC and Investigator radiological assessment, defined as the interval between the date of T-cell infusion and the earliest date of disease progression or death due to any cause.

    Time frame: 3.6 years

  7. Overall Response (OR)

    OR is defined as incidence of (confirmed) complete responses or partial responses as assessed by RECIST v1.1 by Investigator radiological assessment from T-cell infusion until documented disease progression

    Time frame: 3.6 years

  8. Overall Survival (OS)

    OS, defined as the duration between the date of T-cell infusion and the date of death due to any cause.

    Time frame: 15 years

  9. Levels of serum CA125

    Levels of serum CA125 (u/ml) for all patients

    Time frame: 3.6 years

  10. Levels of serum CA125

    Changes of serum CA125 (u/ml) from baseline for all patients

    Time frame: 3.6 years

  11. To characterize the surrogates of treatment effect

    Peak expansion (DNA copies/μg) (i.e., maximum persistence) by responder status and overall (all patients)

    Time frame: 3.6 years

  12. To characterize the surrogates of treatment effect

    Time to peak expansion (in days since T-cell infusion) by responder status and overall (all patients)

    Time frame: 3.6 years

07

Study locations

23 sites
  • Honor Health
    Scottsdale, Arizona 85258, United States
  • City of Hope
    Duarte, California 91010, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Rutgers Cancer Institute of NJ
    New Brunswick, New Jersey 08901, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • University Health Network (Princess Margaret Cancer Center)
    Toronto, Ontario M5G 2M9, Canada
  • Institut de Cancerologie des Hospices Civils de Lyon
    Pierre-Bénite, Lyon 69310, France
  • Centre Leon-Berard
    Lyon, 69008, France
  • Institut de Cancerologie de Strasbourg
    Strasbourg, 67200, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Vall d'Hebron Unversity Hospital
    Barcelona, 08035, Spain
  • Clinica Universidad de Navarra
    Madrid, 28027, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Centro Oncologico Clara Campal
    Madrid, 28050, Spain
  • Hospotal Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • University College of London Hospital
    London, NW1 2PG, United Kingdom
  • The Christie Hospital
    Manchester, M20 4GJ, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2023 to primary completion in Sep 2025, 27 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Aug 2026 → Sep 2025 and completion Aug 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Nov 1, 2022
StartActual
Jun 26, 2023
Primary completionActual
Sep 30, 2025was Aug 2026
CompletionActual
Sep 24, 2026was Aug 2026
Results delay requested
Sep 21, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.
changed Oct 19, 2026
Primary completion
Aug 12, 2026→Sep 30, 2025 (actual)
Oct 19, 2026
Study completion
Aug 12, 2026→Sep 24, 2026 (actual)
Oct 19, 2026
Enrollment
66 (estimated)→21 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Terminated
    Why stopped Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.
    Primary completion Aug 12, 2026→Sep 30, 2025 (now actual)
    Study completion Aug 12, 2026→Sep 24, 2026 (now actual)
    Enrollment 66 (estimated)→21 (actual)
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05601752
Lead sponsor
USWM CT, LLC
Collaborators
GOG Foundation
Responsible party
Sponsor
First posted
Nov 1, 2022
Start date
Jun 26, 2023
Primary completion
Sep 30, 2025
Completion
Sep 24, 2026
Last update
Oct 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion